Q1 2027 Zydus Lifesciences Ltd Earnings Call Transcript

Aug 11, 2026 / 10:30 AM GMT

Release Date Price: ₹1180 (+5.29%)

Transcript

Key Points

Positve

Consolidated net sales grew 66.7% year-on-year, with the international business (including ComfortClick) delivering like-to-like growth of 24.8%.
Gross margin expansion in the core business remained strong, further supported by the significantly higher margin of the ComfortClick business.
EBITDA grew 55.3% to Rs. 2,417 million, with overall EBITDA percentage expanding by approximately 0.4% on a like-to-like basis.
Net profit excluding amortization of acquired brands registered a growth of 26.5% for the quarter.
The company launched several innovative products, including Complan Power Play Milkshake and VMAX Diabetes Care, strengthening its premium, science-led portfolio.
ComfortClick business became EPS accretive from Q4 of the last financial year and continues to be so, with strong growth in the US and Middle East through new launches and D2C platforms.
Domestic portfolio showed strong momentum in skin and hair care (34.5% growth) and food and nutrition (16% growth), with organized channel saliency reaching an industry-leading 38%.
The company successfully transitioned from a GBP loan to a Euro loan at a much reduced interest rate, lowering interest costs.
NiteBite Max Protein continued its strong growth trajectory, reinforcing leadership in protein snacking through innovation and distribution expansion.
Sugarfree maintained category leadership with double-digit growth in the core portfolio, and Sugarfree Delight delivered high double-digit growth.

Negative

Net profit declined by 7% during the quarter, impacted by higher amortization and a one-time tax disallowance due to thin capitalization rules in the UK.
Seasonal brands declined by 12% due to frequent summer showers in eastern and northern India, disrupting the usual summer consumption pattern.
NICEL's performance was significantly impacted by unseasonal rainfall in key saliency markets (north and east), along with cautious channel stocking and slower offtake due to higher retailer inventory from the previous year.
Glucon-D registered a flattish quarter, with weakness in the east offsetting double-digit growth in west and south.
The effective tax rate for Q1 FY27 was close to 27%, higher than the expected 25%, due to disallowance of certain items under the thin cap rule in the UK.
Ongoing geopolitical disruptions continue to create uncertainty, though their impact has been limited so far.
The company noted that the US business for ComfortClick is still very small, making it too early to predict its future contribution as a meaningful growth driver.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZYDU.NS - Zydus Lifesciences Ltd
Q1 2027 Zydus Lifesciences Ltd Earnings Call
Aug 11, 2026 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Zydus Wellness Limited Q1 FY27 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing then 0 on your touch tone phone. Please note that this conference is being recorded. I now hand the conference over to. Mr. Aniket Kamble, thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Hi, it's an absolute

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.